Bloomberg Reported Late Thursday Labcorp Is in Talks to Merge Part of Covance With Syneos Health
https://www.bloomberg.com/news/articles/2021-11-12/labcorp-is-said-in-talks-to-merge-part-of-covance-with-syneos
Barclays Upgrades Syneos Health to Overweight, Raises Price Target to $115
Barclays analyst Luke Sergott upgrades Syneos Health (NASDAQ:SYNH) from Equal-Weight to Overweight and raises the price target from $98 to $115.
Keybanc Maintains Overweight on Syneos Health, Raises Price Target to $105
Keybanc analyst Donald Hooker maintains Syneos Health (NASDAQ:SYNH) with a Overweight and raises the price target from $100 to $105.
Syneos Health’s Return On Capital Employed Overview
According to Benzinga Pro, during Q3, Syneos Health (NASDAQ:SYNH) earned $113.36 million, a 35.46% increase from the preceding quarter. Syneos Health also posted a total of $1.35 billion in sales, a 5.12% increase since Q2.
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
NOVN: Syneos Selected as Commercialization Partner
By John Vandermosten, CFA
NASDAQ:NOVN
READ THE FULL NOVN RESEARCH REPORT
September Update
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)